Small interfering RNA against interleukin-5 decreases airway eosinophilia and hyper-responsiveness

Kay AB, Phipps S, Robinson DS . A role for eosinophils in airway remodelling in asthma. Trends Immunol 2004; 25: 477–482.

Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323: 1033–1039.

Filley WV, Holley KE, Kephart GM, Gleich GJ . Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet 1982; 2: 11–16.

Sanderson CJ . Interleukin-5, eosinophils, and disease. Blood 1992; 79: 3101–3109.

Yamaguchi Y, Suda T, Suda J, Eguchi M, Miura Y, Harada N et al. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med 1988; 167: 43–56.

Sanderson CJ . Interleukin-5: an eosinophil growth and activation factor. Dev Biol Stand 1988; 69: 23–29.

Collins PD, Marleau S, Griffiths-Johnson DA, Jose PJ, Williams TJ . Cooperation between interleukin-5 and the chemokine eotaxin to induce eosinophil accumulation in vivo. J Exp Med 1995; 182: 1169–1174.

Wiktor-Jedrzejczak W . Eosinophil development. Immunol Today 1993; 14: 238.

Fujisawa T, Kato Y, Nagase H, Atsuta J, Terada A, Iguchi K et al. Chemokines induce eosinophil degranulation through CCR-3. J Allergy Clin Immunol 2000; 106: 507–513.

Dubucquoi S, Desreumaux P, Janin A, Klein O, Goldman M, Tavernier J et al. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med 1994; 179: 703–708.

Walker C, Virchow Jr JC, Bruijnzeel PL, Blaser K . T cell subsets and their soluble products regulate eosinophilia in allergic and nonallergic asthma. J Immunol 1991; 146: 1829–1835.

Till S, Li B, Durham S, Humbert M, Assoufi B, Huston D et al. Secretion of the eosinophil-active cytokines interleukin-5, granulocyte/macrophage colony-stimulating factor and interleukin-3 by bronchoalveolar lavage CD4+ and CD8+ T cell lines in atopic asthmatics, and atopic and non-atopic controls. Eur J Immunol 1995; 25: 2727–2731.

Humbert M, Corrigan CJ, Kimmitt P, Till SJ, Kay AB, Durham SR . Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med 1997; 156: 704–708.

Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR . Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol 1993; 92: 313–324.

Kopf M, Brombacher F, Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ et al. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity 1996; 4: 15–24.

Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG . Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996; 183: 195–201.

Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144–2148.

Kips JC, O’Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003; 167: 1655–1659.

Buttner C, Lun A, Splettstoesser T, Kunkel G, Renz H . Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 2003; 21: 799–803.

Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005; 60: 693–696.

Popescu FD . Antisense- and RNA interference-based therapeutic strategies in allergy. J Cell Mol Med 2005; 9: 840–853.

Lee HJ, Koyano-Nakagawa N, Naito Y, Nishida J, Arai N, Arai K et al. cAMP activates the IL-5 promoter synergistically with phorbol ester through the signaling pathway involving protein kinase A in mouse thymoma line EL-4. J Immunol 1993; 151: 6135–6142.

Wang JM, Rambaldi A, Biondi A, Chen ZG, Sanderson CJ, Mantovani A . Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol 1989; 19: 701–705.

Dorman SC, Sehmi R, Gauvreau GM, Watson RM, Foley R, Jones GL et al. Kinetics of bone marrow eosinophilopoiesis and associated cytokines after allergen inhalation. Am J Respir Crit Care Med 2004; 169: 565–572.

Park CS, Choi YS, Ki SY, Moon SH, Jeong SW, Uh ST et al. Granulocyte macrophage colony-stimulating factor is the main cytokine enhancing survival of eosinophils in asthmatic airways. Eur Respir J 1998; 12: 872–878.

Kung TT, Stelts DM, Zurcher JA, Adams III GK, Egan RW, Kreutner W et al. Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody. Am J Respir Cell Mol Biol 1995; 13: 360–365.

Corry DB, Folkesson HG, Warnock ML, Erle DJ, Matthay MA, Wiener-Kronish JP et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 1996; 183: 109–117.

Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 2004; 113: 115–119.

Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol 2006; 118: 1133–1141.

Karras JG, McGraw K, McKay RA, Cooper SR, Lerner D, Lu T et al. Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma. J Immunol 2000; 164: 5409–5415.

Pebernard S, Iggo RD . Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation 2004; 72: 103–111.

Lee CC, Huang HY, Chiang BL . Lentiviral-mediated GATA-3 RNAi decreases allergic airway inflammation and hyperresponsiveness. Mol Ther 2008; 16: 60–65.

Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003; 21: 635–637.

Saxena S, Jonsson ZO, Dutta A . Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 2003; 278: 44312–44319.

Lee YL, Ye YL, Yu CI, Wu YL, Lai YL, Ku PH et al. Construction of single-chain interleukin-12 DNA plasmid to treat airway hyperresponsiveness in an animal model of asthma. Hum Gene Ther 2001; 12: 2065–2079.

Chuang YH, Fu CL, Lo YC, Chiang BL . Adenovirus expressing Fas ligand gene decreases airway hyper-responsiveness and eosinophilia in a murine model of asthma. Gene Therapy 2004; 11: 1497–1505.

Glaab T, Mitzner W, Braun A, Ernst H, Korolewitz R, Hohlfeld JM et al. Repetitive measurements of pulmonary mechanics to inhaled cholinergic challenge in spontaneously breathing mice. J Appl Physiol 2004; 97: 1104–1111.